Symposia


WIN 2024 Symposium
March 01 - 02, 2024

It is our honor and pleasure to join efforts with the Burjeel Holdings to deliver this WIN Symposium in Abu Dhabi, UAE on 1-2 March 2024.

Under the theme of “Precision and Molecular Oncology: Caring for Patients and Future Generations,” this symposium aims to bring together expert clinicians, researchers, and industry professionals from around the world to discuss and explore the latest advancements in precision oncology.

Endorsed by the American Society of Clinical Oncology (ASCO®). ‘ASCO® is a registered trademark of the American Society of Clinical Oncology®. Used with permission. This is not an ASCO sponsored event’.

Accredited for 8.5 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®).

The scientific and organizing committee have curated an exciting program that includes thought leaders in precision oncology including Nobel Laureate Jim Allison (MD Anderson Cancer Center, USA).

The WIN Symposium will provide attendees with a deep understanding of the role of key biomarkers, their optimal application, and emerging new omic tests that will inform future biomarker adoption under the two big umbrellas of Precision Genomics and Precision Immunotherapy. Local experience from the UAE, the host country, will be included to link global evidence to regional practice. Application of the principles of precision medicine will be discussed beyond medical and onto radiation oncology along with issues of access, equity and diversity in precision oncology practice and trials on a global scale. The symposium will feature a Molecular Tumor Board to exemplify with real patient cases how to use biomarkers to inform therapeutic choices. Finally, a panel discussion will be dedicated to navigating available diagnostic pathways and tests from bench to bedside.
The symposium will also feature networking opportunities, allowing participants to connect with peers, establish collaborations, and forge new partnerships.

It is exciting to see the WIN Symposium program come together as a superb international medical and scientific meeting that can serve students, residents, fellows, established clinicians, and researchers who are pursuing state-of-the-art precision oncology practice, research breakthroughs and innovative clinical trials. We hope you find this meeting educational and practice changing.

Visit https://win-burjeel-symposium.com/ to register, submit an abstract and further information.

 



Friday, March 01, 2024

Session 1: Grand Opening

Speakers

Chairperson: Prof. Khaled Musallam, Burjeel Holdings



Cancer Care and Research in the UAE

Speakers

Prof. Humaid Al-Shamsi, Burjeel Holdings




WIN Consortium: Past, Present, Future

Speakers

Prof. Razelle Kurzrock, WIN Consortium/MCW Cancer Center Prof. Wafik El-Deiry, WIN Consortium/Brown University




Opening Ceremony

Speakers



Keynote Lecture
Immune Checkpoint Blockade in Cancer Therapy: New Insight into Mechanisms of anti-CTLA-4, anti-PD-1, and Combination

Speakers

Prof. James Allison, Nobel Laureate, MD Anderson Cancer Center



Session 2: Precision Genomics: From Bench to Bedside

Speakers

Chairpersons: Prof. Garth Powis, PHusis Prof. Wafik El-Deiry, WIN Consortium/Brown University



A Visionary Odyssey Beyond Boundaries: The Evolution of Tumor-Agnostic Drug Development in Precision Medicine

Speakers

Dr. Vivek Subbiah, Sarah Cannon Research Institute



Therapeutic Targeting of EMT and Tumor Plasticity

Speakers

Prof. Sendurai Mani, Brown University




Role of Liquid Biopsy in Targeted Therapy

Speakers

Dr. Hatim Husain, UC San Diego




The Emirati Genome Program: A National Enabler of Precision Medicine

Speakers

Dr. Mohamed AlAmeri, Department of Health Abu Dhabi



Roadmap for Precision Genomics in Routine Cancer Care in the UAE

Speakers

Prof. Faisal Khan, University of Calgary and OncoHelix & coLAB, Burjeel Holdings



Session 3: Precision Immunotherapy: The Next 5 Years

Speakers

Chairpersons: Prof. James Allison, MD Anderson Cancer Center Prof. Padmanee Sharma, MD Anderson Cancer Center



Integrating Clinical and Laboratory Research to Identify Mechanisms of Response and Resistance to Immune Checkpoint Therapy

Speakers

Prof. Padmanee Sharma, MD Anderson Cancer Center



Role of Liquid Biopsy in Immunotherapy

Speakers

Prof. Christian Rolfo, Icahn School of Medicine at Mount Sinai and International Society of Liquid Biopsy [ISLB]



Transcriptomics at WIN: Opening the Multi-omic Era

Speakers

Dr. Vladimir Lazar, WIN Consortium



Landscape of Immunotherapy in the UAE

Speakers

Dr. Hassan Jaafar, Burjeel Medical City



Session 4: Precision Research

Speakers

Chairpersons: Prof. Humaid Al-Shamsi, Burjeel Holdings Prof. Khaled Musallam, Burjeel Holdings



Landscape of Translational Cancer Clinical Trials in the UAE

Speakers

Mohamed Mostafa, PDC-CRO, UAE



Oral Abstracts and Awards

Speakers



Saturday, March 02, 2024

Session 5: Molecular Tumor Board

Speakers

Chairpersons: Prof. Razelle Kurzrock, WIN Consortium/MCW Cancer Center Prof. Wafik El-Deiry, WIN Consortium, Brown University



Interactive Session with Cases from the UAE

Speakers



Session 6: Radiation Oncology in Precision Medicine

Speakers

Chairpersons: Dr. Ibrahim Abu-Gheida, Burjeel Medical City Dr. Shahin Fattahi, Burjeel Medical City



A Genomic Adjusted Radiation Dosing Paradigm to Biologically Personalize Radiation Therapy

Speakers

Dr. Jacob Scott, Cleveland Clinic



Radiotherapy as Immunotherapy for Cancer

Speakers

Prof. Silvia Formenti, Weill Cornell Medicine



Session 7: Precision Communityomics

Speakers

Chairpersons: Prof. Wafik El-Deiry, WIN Consortium/Brown University Prof. Don Dizon, Brown University



Diversity and Equity in Precision Oncology

Speakers

Prof. Don Dizon, Brown University



Tools for Precision Communityomics

Speakers

Dr. Katherine Tossas, Virginia Commonwealth University



Session 8: Precision Diagnostics

Speakers

Chairpersons: Dr. Alison Finall, Burjeel Medical City Dr. Pinaki Bose, University of Calgary and OncoHelix, & coLAB, Burjeel Holdings



Panel Discussion

Speakers

Prof. Christian Rolfo, Icahn School of Medicine at Mount Sinai and International Society of Liquid Biopsy [ISLB] Dr. Hatim Husain, UC San Diego Dr. Helmy Eltoukhy, Guardant Health Dr. Jason Hipp, Mayo Clinic Dr. Justin Guinney, Tempus AI


Past events


Partnership The Journal of Immunotherapy and Precision Oncology (JIPO) and WIN

Partnership The Journal of Immunotherapy and Precision Oncology (JIPO) and WIN
December 28 - 28, 2024

JIPO and WIN renew their cooperation to cover the WIN 2024 symposium 1-2 March 2023 in Abu Dhabi, UAE.
JIPO will publish the symposium abstracts.


WIN 2022 Symposium

WIN 2022 Symposium
October 29 - 30, 2022

The WIN 2022 Symposium ‘Integrating Genomics and Transcriptomics to Reshape Precision Oncology: A WINning Strategy’ took place on 29-30 October, 2022 in Barcelona, Spain.

We had an exciting line-up of prominent speakers and panel discussion and our 1st international molecular board!

 



WIN 2022 Program

Speakers




Speakers


Partnership JIPO and WIN

Partnership JIPO and WIN
December 03 - 03, 2022

JIPO and WIN cross-promoted each other’s organization’s activities throughout the year, including the WIN 2022 Symposium in Barcelona, Spain, October 29-30, 2022. Abstracts selected for presentation at the WIN meeting were published in JIPO as a Conference Proceeding.

JIPO Editorial Fellow, Dr. Khalid Jazieh, interviewed members of WIN Leadership to highlight the collaboration and upcoming activities. Drs. Razelle Kurzrock, Vladimir Lazar, and Richard L. Schilsky were interviewed. These interviews were published on the JIPO YouTube channel.

Dr. Vladimir Lazar, Chief Scientific and Operating Officer of WIN, was appointed to the JIPO Editorial Board to represent WIN Leadership. Dr. Lazar contributed to an editorial to the Journal in 2022. Dr. Kurzrock has published four articles in JIPO in 2019 and 2020.


WIN 2019 Symposium

WIN 2019 Symposium
June 23 - 24, 2019

The 11th edition of the WIN Symposia ‘WINnovation and Global Deployment of Precision Oncology’ took place in Paris, France on 23-24 June 2019.



Sunday, June 23, 2019

Welcome & Opening Remarks

Speakers

Richard L. Schilsky



Lifestyle-based Prevention Strategies

Speakers

Jennifer A. Ligibel



Rewriting the Code of Life: CRISPR-Cas Genome editing

Speakers

Jennifer A. Doudna



Innovation in Clinical Trials: WINTHER trial

Speakers

Razelle Kurzrock



Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials

Speakers



Innovation in Clinical Trials: SPRING_01 Proof of Concept Trial exploring Combination of Three Targeted Drugs



Systems Immunology in IO: A view from the Parker Institute

Speakers

Nikesh Kotecha



Innovative Ways of Assessing Durable Response to Immunotherapy

Speakers

Christophe Le Tourneau



Monday, June 24, 2019

Direct Targeting of STAT3 Alone and in Combination with Immune Checkpoint Inhibitors to Treat Solid Tumors

Speakers

David J. Tweardy



CDK4/6 Inhibitors in Breast Cancer; today's real and future dream

Speakers

Hikmat Abdel-Razeq



The Value of Personalized Medicines for Healthcare Systems in Europe - Considering enablers to the adoption of personalized medicines in Europe

Speakers

Anthony Barron



Development and Application of Precision Oncology in China

Speakers

Hu Xin



National Cancer Grid of India - Earthshots over Moonshots

Speakers

C.S. Pramesh



Innovative Algorithms and IT Platform to Support Clinical Trials

Speakers

Eitan Rubin



Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations

Speakers

Funda Meric-Bernstam



Oncobox, RNA Sequencing and Molecular Pathway Analysis-Based Second Opinion System for Prescription of Target Drugs to Advanced Cancer Patients: Concept, Design and Results of Clinical Trials

Speakers

Anton Buzdin



Matched Tumor/Normal Expression Profiling from Small FFPE Samples

Speakers

Debrah Thompson


WIN 2018 Symposium

WIN 2018 Symposium
June 25 - 26, 2018

The 10th year Anniversary edition of the WIN Symposia took place at the WIN Symposium 2018 in Paris, France on 25-26 June 2018.
The WIN Symposium Organizing Committee had chosen “Global Implementation of Precision Oncology: WINning the War against Cancer” as the theme for this celebratory event.




Speakers



Celebrating 10 years of the WIN Symposium

Speakers



Final Program of WIN Symposium 2018

Speakers



Monday, June 25, 2018

The TAPUR Family of Clinical Trials: Building a Global Data Sharing Platform in Precision Oncology

Speakers



NCI's Integrated Precision Oncology Networks

Speakers

James H. Doroshow



The WIN Consortium BOOSTER trial for identification and validation of new blood biomarkers for NSCLC

Speakers

Amir Onn



How Robust Are Your Archives?

Speakers

Harvey I. Pass



Patients Driving Progress

Speakers

Ellen V. Sigal



Tuesday, June 26, 2018

MyPathway Study: A Novel Precision Oncology Multiple Basket Trial

Speakers

Mary Beattie



Precision CAR T cells Therapeutics

Speakers

Carl H. June



Precision Oncology Approaches for Immunotherapy

Speakers

Eric Rubin



Early development in oncology: Are the MTD and monotherapy efficiacy still the best objectives?

Speakers

Giorgio Massimini, Merck KGaA



Implementing Precision Medicine in Oncology: The IMPACT Clinical Trials at MD Anderson Cancer Center

Speakers

Apostolia M. Tsimberidou, UT, MDACC



The 'Greatest Hits' of Precision Oncology: the view from the newsroon

Speakers

Bernadette Toner



Patients' access to Precision Oncology



Dynamic monitoring HER2 amplification of circulating DNA in metastatic colorectal cancer patients treated with cetuximab

Speakers

Best Poster Award winner: Rujiao Liu et al.


WIN 2017 Symposium

WIN 2017 Symposium
June 26 - 27, 2017

The WIN 2017 Symposium with the theme ‘Expediting Global Innovation in Precision Cancer Medicine’ was held in Paris, France, June 26-27, 2017. The overarching goal of our symposium was to share information to promote and accelerate cutting edge investigations and use of personalized, targeted cancer therapy.



Highlights from the WIN 2017 Symposium, 26–27 June 2017, Paris, France: ‘Expediting Global Innovation in Precision Cancer Medicine’

Speakers

ecancer Medical Science Conference Report


WIN 2016 Symposium

WIN 2016 Symposium
June 27 - 28, 2016

The WIN 2016 Symposium “Innovative Approaches to Improve Cancer Patient Outcomes”, June 27-28th was the eighth in a series of symposia dedicated to advancing personalized cancer medicine. It was a successful unique forum that brought leaders representing all stakeholders - academia, pharma, biotech / life sciences, regulatory, and health payer - together from around the globe.


Plenary Session 1: Welcome and Opening remarks:
Monday, June 27, 2016

Welcome

Speakers

WIN Chairman


Patients' and Advocacy Groups Perspectives:

No innovation about us without us

Speakers

Francesco de Lorenzo



Patient perspectives

Speakers

Matt Ellefson


Plenary Session 2: New tools for early diagnosis, selecting therapies and monitoring:


Speakers

Chairmen: Alex Drilon, Don Gibbons


Part 1: New Strategies to Improve Outcomes:

Keynote Lecture: A systems biology approach to elucidating and targeting functional tumor dependencies from patient-derived RNASeq profiles

Speakers

Andrea Califano



Affordable next-generation sequencing to support therapeutic decision-making

Speakers

Elaine Mardis


Part 2: Enabling Technologies: Opportunities for Liquid Biopsies:

Monitoring the cancer genome in plasma using circulating tumor DNA

Speakers

Nitzan Rosenfeld



Serum miRNAs as diagnostic and prognostic tools in GI malignancies

Speakers

Ajay Goel



Harnessing the biology of exosomes for diagnosis and treatment of cancer

Speakers

Raghu Kalluri


Part 3: A Scientist's View of Tumor Changes under Therapeutic Pressure:

Liquid biopsies to track clonal evolution and resistance to EGFR inhibition in mCRC

Speakers

Alberto Bardelli


Plenary Session 3: Innovative clinical trials to substantially improve outcome:


Speakers

Chairpersons: Razelle Kurzrock, Christophe Le Tourneau


Part 1: Immune Approaches and Combinations of Targeted Therapies:

Keynote Lecture: Paths to the Curative Treatment of Cancer, ABL001: A Future Case Study?

Speakers

William Sellers



Combination trial designs: How do we get efficiently to the most effective and tolerable combination regimen?

Speakers

Susan Galbraith


Part 2: Right Treatment Sequencing:

Towards Using Epigenetic Therapy to Improve Cancer Immunotherapy

Speakers

Daniel De Carvalho


Part 3: Forum: Is the Current Design of Precision Medicine Studies the Right One? Lessons from the Shiva Trial:

Pro Presentation

Speakers

Christophe Le Tourneau



Con Presentation

Speakers

Razelle Kurzrock


Plenary Session 4: Relevant models and critical preclinical data before moving to the clinic:
Tuesday, June 28, 2016


Speakers

Chairmen: Alan Spatz, Brian Leyland-Jones



Keynote Lecture: Scientific wellness and cancer

Speakers

Leroy Hood



Preclinical strategies for precision medicine in colorectal cancer: Challenges and opportunities

Speakers

Livio Trusolino



Cancer organoids: Limiting the need for animal models?

Speakers

Robert G.J Vries



New challenges in drug development


Special Plenary Session:

Results of MINDACT clinical trial

Speakers

Chairpersons: Martine Piccart, Thomas Tursz Suzette Delaloge


Plenary Session 5:

Expediting precision cancer medicine

Speakers

Forum chaired by John Mendelsohn, Participants: Martine Piccart, Bruce E. Johnson, Amir Onn, Richard L. Schilsky, William Sellers, Josep Tabernero, Thomas Tursz, Chang Sik Yu


Plenary Session 6: Translation of big data into clinical opportunities:


Speakers

Chairmen: Eitan Rubin, Yves Lussier


Part 1: Lung cancer:

Keynote Lecture: The impact of next generation sequencing on the outcomes of patients with lung cancer

Speakers

Bruce E. Johnson


Part 2: Colorectal cancer:

CRC subtypes: from molecular signatures to therapeutic opportunities

Speakers

Rodrigo Dienstmann


Part 3: Breast cancer:

Personalizing breast cancer therapy

Speakers

Funda Meric-Bernstam


Part 4: Debate: Is big data ready to improve patient outcomes or is it a new generation of garbage in/ garbage out?:

Pro presentation/Con presentation

Speakers

Yves Lussier Gordon B. Mills






WIN 2015 Symposium

WIN 2015 Symposium
June 29 - 30, 2015

The WIN 2015 Symposium, on the theme of “Novel Targets, Innovative Agents, Advanced Technologies: A WINNing Strategy?” featured a global array of many of the world’s leading experts in personalized cancer medicine - from academia, pharma, biotech, and governmental organizations.


Plenary Session 1: Opening:
Monday, June 29, 2015

Opening Addresses

Speakers


WIN 2015 Keynote Opening Lecture:

The Era of Precision Cancer Medicine: A worldwide effort and challenge - Introduction to WIN Consortium

Speakers


Plenary Session 2: Targeting immune mechanisms:
Monday, June 29, 2015


Speakers

Chairmen: Alexander Eggermont, Robert Iannone


Keynote Lecture:

Targeting immune mechanisms

Speakers

James Allison



Natural killer immunity and cancer immunome

Speakers

Angel Porgador



What T-cells see on human cancer

Speakers

Ton Schumacher


Plenary Session 3: Systems biology and new approaches to support personalized cancer care:
Monday, June 29, 2015


Speakers

Chairmen: Thomas Tursz, Chang Sik Yu


Keynote Lecture:

A systems biology approach to precision cancer medicine

Speakers

Andrea Califano



Personalized combinatorial approaches to closing down all the key oncogenic drivers

Speakers

Brian Leyland-Jones



Battle-2 Trial: Mutational landscape and clinical outcome

Speakers

Waun Ki Hong



Drug target activation mapping through a proteomic CLIA assay: A companion diagnostic engine for personalized medicine trials

Speakers

Emanuel F. Petricoin


Plenary Session 4: Next generation of trials with targeted therapies:
Monday, June 29, 2015


Speakers

Chairman: Richard L. Schilsky



Round table of pharma and academic experts

Speakers

Richard L. Schilsky



WINTHER trial: Interim results and lessons learnt

Speakers

Jean-Charles Soria



WINTHER trial: An SME driven EUFP7 program to create an industry standard tool to optimize therapeutic decision making

Speakers


Plenary Session 5: WIN Consortium - next generation of trials with targeted therapies:
Monday, June 29, 2015


Speakers

Chairmen: John Mendelsohn, Waun Ki Hong



SIMS - Simplified INterventional Mapping System for the identification of druggable activated pathways

Speakers



SPRING - Rolling tri-therapy combinations of targeted drugs in second line of metastatic NSCLC

Speakers

Razelle Kurzrock



SUMMER - Elimination of relapse through innovative adjuvant targeted therapeutics in stage II and III NSCLC

Speakers

Don L. Gibbons



BOOSTER - An integrative program for the discovery & validation of new blood biomarkers for NSCLC for use in early diagnosis (stage I)

Speakers

Harvey Pass



Oral presentation of awarded posters

Speakers

Chairpersons: Catherine Bresson, Marinus Lobbezoo


Plenary Session 6: New avenues: Big trials and big data:
Tuesday, June 30, 2015


Speakers

Chairpersons: Katherine Galvin, Benjamin Neel


Keynote Lecture:

A perspective on NCI strategy and trials

Speakers

James Doroshow



ASCO's initiatives in personalized medicine

Speakers



Meta analyses of 50,000 patients in personalized cancer trials

Speakers

Razelle Kurzrock



New avenues for the development and evaluation of therapy

Speakers


Plenary Session 7: Multi-modality and multi-drug cancer therapy:
Tuesday, June 30, 2015


Speakers

Chairmen: C.S. Pramesh, Scott M. Lippman



Bottleneck problems in mutation-driven drug development and immunotherapy

Speakers

Alexander M. Eggermont



Combinating radiation and immunotherapy

Speakers

Ralph Weichselbaum


Plenary Session 8: Recent progress in specific tumor types:
Tuesday, June 30, 2015


Speakers

Chairmen: Jean-Francois Martini, Filippo de Braud



Intrinsic subtypes of colon cancer and their response to systemic therapy

Speakers



What is new in melanoma?

Speakers

Iman Osman



Cancer genomics of urothelial cancer and fibroepithelial tumors of the breast

Speakers

Bin T. Teh


Plenary Session 9: Regulatory and funcing challenges in the era of personalized cancer medicine:
Tuesday, June 30, 2015


Speakers

Chairmen: Richard L. Schilsky, Kenneth Seamon


Keynote Lecture:

The EMA adaptive pathways approach to improve timely access for patients to new medicines

Speakers

Francesco Pignatti



End points and assessment of therapeutic efficacy in personalized cancer care

Speakers

Tatiana Powell



Importance of methodology certification and accreditations to perform assays



Use of targeted therapies and challenges for health payers

Speakers

Carole Redding Flamm



Challenges for foundations and cancer research organizations

Speakers

Jacques Raynaud



WIN2015 - Open Forum & Closing Remarks

Speakers


WIN 2014 Symposium

WIN 2014 Symposium
June 23 - 24, 2014

The WIN 2014 Symposium which was held in Paris, June 23 and 24, 2014, was an exceptional global event entirely dedicated to breakthrough biomarker investigations and combination therapies for cancer. Over 400 delegates from more than 35 countries worldwide attended the Symposium.


Opening and Welcome Addresses:
Monday, June 23, 2014

Welcome Address

Speakers



WIN Consortium: Goals and strategy

Speakers

John Mendelsohn, WIN Consortium


Opening Address:

Another great journey: WIN in 21st century

Speakers

Trent Haywood, Blue Cross Blue Shield Association


Plenary Session 1:
Monday, June 23, 2014

Molecular analysis of immune cells and immunotherapy

Speakers


Keynote Lecture:

Reinstating immunosurveillance: A prime goal of anticancer therapies and a strategic element for combination treatments

Speakers

Guido Kroemer



Molecular investigations of immune cells and tumor environment: The Ovarian Cancer Model

Speakers

George Coukos



Combining immunological and targeted agents: The way forward

Speakers

Axel Hoos



Tumor-infiltrating immune cells as classifiers and predictors of outcome

Speakers

Jerome Galon




Plenary Session 2:
Monday, June 23, 2014

What can we learn from hemato-oncology?

Speakers


Keynote Lecture:

Molecular pathways in the treatment of leukemia

Speakers

Bob Lowenberg



Role of mutations in epigenetic regulators in pathogenesis of myeloid malignancies

Speakers

Ross Levine



Combining interferon with targeted therapeutics to eliminate leukemia propagating cells in myeloproliferative neoplasms

Speakers

Eric Solary



Combination therapies in hematologic diseases

Speakers

Jesus Gomez Navarro



Systems medicine approach to optimize drugs and drug combinations for individual AML patients

Speakers

Olli Kallioniemi



General Discussion, Session 2

Speakers


Plenary Session 3:
Monday, June 23, 2014

Innovative therapeutic initiatives and models of cooperation

Speakers



Perspectives for effective cancer drug development: The EORTC SPECTA initiative

Speakers

Denis Lacombe



Clinical trial designs for incorporating multiple biomarkers in combination studies with targeted agents

Speakers

J. Jack Lee



General Discussion, Session 3

Speakers



Monday, June 23, 2014

POSTER AWARDING CEREMONY AND PRESENTATION OF AWARDED POSTERS

Speakers



Introduction Poster Award

Speakers



Oral presentation Summary Poster P4.01: Somatic mutation analysis in clinical tumour samples to select patients for experimental therapies

Speakers

Maider Ibarrola-Villava, et al



Oral presentation Summary Poster P5.06: Targeted delivery of a microRNA mimic as a novel approach to therapy for malignant pleural mesothelioma

Speakers

Glen Reid, et al


WIN CHAIRMAN’S LECTURE:

Personalized cancer therapy: Successes and challenges

Speakers


Plenary Session 3:
Tuesday, June 24, 2014

Combinations of targeted therapies (part 1)

Speakers


Keynote Lecture:

Complexity of intra- and inter-pathway loops in colon cancer and melanoma: Implications for targeted therapies

Speakers

Rene Bernards



Genomic complexity of metastatic disease and the conundrum of combinations

Speakers

Razelle Kurzrock



Biology driven combination therapies: How to turn up the HEAT on cancer – A PhRMA perspective

Speakers



Combinations of targeted therapies in oncology – An industry view

Speakers

Susan Galbraith



General Discussion, session 4

Speakers


Plenary Session 4:
Tuesday, June 24, 2014

Combinations of targeted therapies (part 2)

Speakers



The challenges of combinations of targeted agents in oncology

Speakers

Tal Zaks



Impact of the BATTLE trial

Speakers

Waun Ki Hong



Combining radiotherapy with immunotherapy in metastatic cancer

Speakers

Silvia Formenti


Keynote Lecture:

Growing tissue stem cells into organoids and tumeroids: Predictive assay development

Speakers

Hans Clevers


Plenary Session 5:
Tuesday, June 24, 2014

New findings on fundamental mechanisms in pediatric cancers

Speakers


Keynote Lecture:

Novel drug targets and potential combinations in childhood brain tumors

Speakers

Stefan Pfister



Pediatric high grade brain tumors: Epigenetic addiction of the developing brain?

Speakers

Nada Jabado


WIN 2014 SPECIAL KEYNOTE LECTURE:

Cancer Stem Cells and Malignant Progression

Speakers

Robert Weinberg


Plenary Session 6:
Tuesday, June 24, 2014

Blood and fluids – non-invasive investigations in oncology

Speakers


Keynote Lecture:

Proactive P4 medicine-making blood a window into health and disease: A tipping point that is transforming healthcare

Speakers



Circulating tumor cells (CTCs) or circulating DNA (cfDNA): What are the perspectives?

Speakers

Caroline Dive



Personalized cancer medicine using the human protein atlas and affibodies

Speakers

Mathias Uhlen



Wrap-up and conclusions

Speakers


WIN 2013 Symposium

WIN 2013 Symposium
July 10 - 12, 2013

The WIN 2013 Symposium, held on the theme of “Personalized Cancer Medicine: From Innovation to Implementation” drew over 400 delegates from around the world. Thirty experts from academia, pharma, diagnostics, bio-informatics companies, and regulatory agencies presented and discussed their views on how new genomic and proteomic technologies and new targeted therapies affect the way individual cancer patients are treated, as well as the hurdles for implementation of personalized cancer therapy in innovative clinical trials and daily practice.